相关实验视频
Updated: Jul 2, 2025

07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.0K
塞马格卢提德可以缓解由高脂肪饮食引起的肠道微生物群失调症
Xinhao Duan1, Lei Zhang2, Yi Liao1
1Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, 400016, China.
European journal of pharmacology
|February 25, 2024
概括
在肥胖小鼠中,塞马格卢提德治疗减少了体重增加和改善了代谢健康. 它还恢复了肠道微生物群的平衡,并修复了肠道屏障功能,这表明肠道细菌在其抗肥胖作用中发挥了作用.
科学领域:
- 代谢性疾病研究研究.
- 微生物组研究研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一种复杂的代谢障碍,通常与肠道失调有关.
- 高脂肪饮食 (HFD) 诱导肥胖并改变肠道微生物群的组成.
- 塞马格卢提德是一种类似于葡萄糖的-1受体激动剂,用于2型糖尿病和肥胖管理.
研究的目的:
- 为了研究食诱导的肥胖小鼠对肠道微生物群的塞马格卢提德的影响.
- 为了确定塞马格卢提德是否可以改善HFD诱导的代谢功能障碍和肠道功能障碍.
- 为了探索肠道微生物群变化与塞马格卢提德抗肥胖作用之间的关系.
主要方法:
- 雄性C57BL/6J小鼠被食HFD以诱导肥胖.
- 小鼠接受了18天的塞马格卢提德或安慰剂治疗.
- 评估了体重,耐葡萄糖,抗胰岛素,肝脂沉积,基因表达,肠道微生物组成和肠道屏障功能.
主要成果:
- 塞马格卢提德显著降低了体重增加,改善了葡萄糖耐受性和降低了胰岛素抵抗力.
- 用西马格卢提德治疗降低了肝脂沉积和正常化相关基因表达.
- 塞马格卢提德调节了肠道微生物群的多样性,恢复了像阿克尔曼西亚这样的有益细菌,减少了有害的细菌,同时也增强了肠道屏障的完整性.
结论:
- 赛马格卢提德有效地减轻肥胖和相关的代谢障碍在小鼠.
- 该药物积极影响肠道微生物群的组成和功能,减轻HFD诱导的功能障碍.
- 肠道微生物群的变化,特别是阿克尔曼西亚的增加,可能会调解塞马格卢提德的抗肥胖作用.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
119
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
119
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141

